Can chronic anti-tumour necrosing factor therapy and colic polyps overwhelm a normal functioning mitral valve? A case report of an endocarditis complicated by a ruptured intracranial mycotic aneurysm. Issue 12 (16th December 2021)

• Record Type: Journal Article
• Authors: Khadir, Karim; Mirica, Daniela; Ligot, Noémie; van de Borne, Philippe
• Editors: Aboumarie, Hatem Soliman; Abdulhak, Aref Bin; Calik, Ali Nazmi; Komorovsky, Roman; Klimis, Harry; Anagnostopoulou, Andriana; Falconer, Debbie; Djahit, Ayse
• Is Part Of: European heart journal. Volume 5:Issue 12(2021)
• Publication Date: 2021-12-16
• Subjects: Streptococcus bovis -- Mitral endocarditis -- Sub-arachnoid haemorrhage -- Mycotic aneurysm -- Etanercept -- Case report; Cardiology -- Periodicals; Cardiology -- Case studies -- Periodicals; Heart -- Diseases -- Periodicals; Heart -- Diseases -- Case studies -- Periodicals; 616.12
• DOI: 10.1093/ehjcr/ytab515
• Languages: English
• ISSNs: 2514-2119

Abstract

Abstract: Background: Rapid identification of endocarditis is challenging but also an important opportunity to change disease course. This is especially true when immunosuppression undermines diagnosis by mitigating symptoms that commonly accompany infectious disease, sometimes in the absence of predisposing heart valve disease as in this case presented here. Case summary: A middle-aged man with chronic etanercept treatment for ankylosing spondylitis, with previously well-documented normal cardiac valves, presented with afebrile chills, night sweating, weight loss, and a new mitral regurgitation at auscultation. This Streptococcus bovis -related endocarditis, in the presence of benign colic polyps, rapidly became complicated by a ruptured infectious intracranial mycotic aneurysm. The patient was successfully cured by endovascular embolization. Severe mitral regurgitation required an uneventful mitral annuloplasty 1 month thereafter. Discussion: Immunosuppression from etanercept treatment was likely responsible for this unspecific clinical presentation and potentially devastating intracranial mycotic aneurysm. This complication is infrequently reported within 6 months of anti-tumour necrosing factor therapy initiation but occurred after more than 11 years of therapy in our patient. This case is a timely reminder of the clinical challenges of endocarditis in immunosuppressed patients and highlights a potential long-term complication of etanercept.